NASDAQ:FUSN - Nasdaq - CA36118A1003 - Common Stock - Currency: USD
Taking everything into account, FUSN scores 3 out of 10 in our fundamental rating. FUSN was compared to 553 industry peers in the Biotechnology industry. FUSN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, FUSN is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -32.2% | ||
ROE | -43.12% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Altman-Z | 11.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 10.64 | ||
Quick Ratio | 10.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
21.55
+0.03 (+0.14%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 898.55 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 7.58 | ||
P/tB | 7.58 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -32.2% | ||
ROE | -43.12% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 278.83% | ||
Cap/Sales | 196.28% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 10.64 | ||
Quick Ratio | 10.64 | ||
Altman-Z | 11.27 |